Nucleus RadioPharma
@nucleusrad
Followers
32
Following
168
Media
14
Statuses
100
Nucleus RadioPharma is a growing end-to-end contract radiopharmaceutical development and manufacturing organization (CDMO)
Davidson, NC
Joined October 2022
This #Movember, the Nucleus RadioPharma team is doing more than growing mustaches; we’re spreading awareness, advancing science, and honoring every man impacted by prostate cancer. https://t.co/6l1DZFJ46B
#ProstateCancer #CancerCare #Radiopharmaceuticals #RLT #Oncology
0
0
0
The #radiopharmaceutical market is projected to nearly double—from US $6.8 billion in 2024 to US $13.4 billion by 2033. This surge isn’t just about more therapies; it’s about fundamentally scaling infrastructure, manufacturing, and delivery. https://t.co/w2MRlEj0Cy
globenewswire.com
Surging multibillion dollar acquisitions and a pipeline of innovative therapies define the current landscape. A strong focus on oncology theranostics,...
0
0
1
The FDA’s recent draft guidance for radiopharmaceuticals represents a defining moment for the field. In our latest blog post, we unpack why the agency is acting now: https://t.co/iSGoL9oWT2
#Radiopharmaceuticals #RLT #CancerCare #Oncology #NucMed #CDMO
nucleusrad.com
What's in the FDA's new draft guidance? Learn how it could impact radiopharmaceutical development, dosing, and patient safety standards.
0
0
0
How Consistent Are Institutions With Lu-177 Therapy? New Data Reveals Big Gaps Learn more from JNM: https://t.co/VYwjESY33q
#Radiopharmaceuticals #Theranostics #NucMed #RLT #Lu177
jnm.snmjournals.org
25122 Introduction: Lutetium-177 DOTATATE and PSMA therapies have become increasingly utilized in cancer treatment. With their rapid adoption, it is unclear how much variability exists in the...
0
0
2
What does it take to lead through change in nuclear medicine? Our Scientific Advisory Board member Dr. Jeremie Calais speaks with Dr. Pierre Vera about his motivations, his journey into nuclear medicine, and the lessons he’s learned along the way. https://t.co/8XhAScmIE0
jnm.snmjournals.org
Dr. Pierre Vera is a nuclear medicine physician and professor at the University of Rouen. He has worked for over 30 y in the fields of functional imaging and translational research. He currently...
0
0
1
Exciting findings from the American Society for Radiation Oncology (ASTRO) meeting: Adding Lu-177 PNT2002 to SBRT more than doubled progression-free survival for men with oligorecurrent prostate cancer. https://t.co/fkuGW9sBTp
#Lu177 #SBRT #RLT #NucMed #Radiopharmaceuticals
auntminnie.com
Two cycles of lutetium-177 PNT2002 before stereotactic body radiation therapy (SBRT) significantly improved progression-free survival.
0
0
1
Early mistakes in radiopharma often resurface later. Learn the five preclinical pitfalls to avoid and how early planning keeps programs on track for clinical success. https://t.co/8m4XRuQ06f
#RLT #NucMed #radiopharmaceuticals #theranostics #CDMO #CancerCare
nucleusrad.com
Discover five common preclinical pitfalls in radiopharma and how proactive planning helps programs advance smoothly into clinical trials.
0
0
0
October is Breast Cancer Awareness Month. Alongside awareness and early detection, innovation in treatment is critical. #RLT research for #breastcancer is advancing, with a growing number of clinical trials investigating new targets. Explore trials: https://t.co/ozcLnJSNxP
0
0
0
We’re growing the Nucleus RadioPharma team and there’s never been a more exciting time to join! Join us in shaping the future of targeted medicine! Explore open positions across departments & apply now: https://t.co/Ki95robmRq
#Radiopharmaceuticals #CDMO #RLT #Oncology #Hiring
0
0
0
#EANM25 kicks off tomorrow and our team has landed in Barcelona, Spain! We can’t wait to learn and share how Nucleus RadioPharma can be your trusted #CDMO partner. #EANM2025 #RLT #Theranostics #EANM #Oncology #NuclearMedicine
0
0
1
The LUMEN-1 trial is the first prospective randomized study investigating [177Lu]Lu-DOTATATE in recurrent meningioma. By targeting #SSTR2, this trial could usher in a new therapeutic paradigm for patients with limited options. https://t.co/1F4lkUY1zH
#Lu177 #RLT
jnm.snmjournals.org
There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy. Somatostatin receptor type 2 (SSTR2) is highly expressed in meningiomas, and SSTR2-...
0
0
0
The FDA's new draft guidance on #radiopharmaceuticals is an important signal of how quickly our field is advancing. Our CEO, Steve Hahn, shared his perspective on why clarity from regulators matters as more therapies move toward approval: https://t.co/FYaqz6ikA1
#NucMed #RLT
biospace.com
With a flurry of recent Big Pharma investment in radiopharmaceutical therapeutics, the FDA issued draft guidance last month in a move former FDA Commissioner Stephen Hahn sees as the regulator...
0
0
1
Learn how diversifying suppliers and embracing an isotope-agnostic model builds the resilience needed to keep programs moving forward in our latest blog: https://t.co/HFY7T4Ld90
#Radiopharmaceuticals #RLT #Isotope #SupplyChain #CDMO
nucleusrad.com
Diversifying isotope and supplier relationships builds resilience in radiopharma. Learn how our model supports reliable development.
0
0
0
In BioProcess International's latest Featured Report, “Biomanufacturing Facilities: Changing with the Times,” our Chief Commercial Officer weighs in on a critical question facing radiopharma developers. Full report here: https://t.co/I36etPq2QF
#RLT #Radiopharmaceuticals
bioprocessintl.com
Learn how forward-thinking companies are transforming biomanufacturing facilities to challenges and capitalize on emerging opportunities
0
0
2
CMS just released the proposed rules for CY2026. From updated reimbursement thresholds to new incentives for domestic isotope production, these nuclear medicine-specific updates could shape how care is delivered and paid for in the coming year. https://t.co/CdmCfelc27
0
0
0
New this week in radiopharma: The @US_FDA has released draft guidance for oncology radiopharmaceutical dosing. They're accepting public comments on this draft guidance until 10/10/2025. Visit https://t.co/KAwH3QNJoo.
#Radiopharmaceuticals #FDA #Oncology #RLT #RPT
fda.gov
Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development
0
0
0
Nucleus RadioPharma is thrilled to announce Stephen Hahn as Chief Executive Officer! Learn more @ Business Wire: https://t.co/XMz7oMVStn STAT: https://t.co/xeElLtOSwD
#RLT #Theranostics #Radiopharmaceuticals #CancerCare #StephenHahn #NucleusRadioPharma
0
0
0
We're Hiring! We have several open positions across departments with opportunities located in: 📍 Rochester, MN 📍 Greater Philadelphia Area https://t.co/ltLKUsmmG6.
#Hiring #Radiopharmaceuticals #RLT #Theranostics
0
0
1
Precursor documentation, isotope sourcing, and GMP planning all play a critical role in radiopharmaceutical development. We partnered with Facet Life Sciences to unpack the CMC considerations that can make or break your IND timeline. Learn more:
nucleusrad.com
Learn how radiopharma developers can avoid common CMC missteps, align early with GMP, and streamline the path from discovery to approval.
0
0
0